Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moderna, Inc.

31.26
-0.9400-2.92%
Post-market: 31.25-0.0100-0.03%19:59 EDT
Volume:7.82M
Turnover:246.38M
Market Cap:12.09B
PE:-3.58
High:32.58
Open:32.45
Low:30.97
Close:32.20
Loading ...

Moderna Inc. Stock Sheds 2.9%, Underperforms Competitors

Dow Jones
·
Yesterday

Moderna Completes Research Facility in Japan, Scraps mRNA Manufacturing Base

MT Newswires Live
·
18 Jul

Moderna cancels plans to build Japan plant on poor business environment

Reuters
·
18 Jul

BRIEF-Moderna Cancels Japan mRNA Plant Plans Amid Weak Demand-Nikkei

Reuters
·
18 Jul

Moderna Cancels Japan Mrna Plant Plans Amid Weak Demand-Nikkei

THOMSON REUTERS
·
18 Jul

Moderna (MRNA) Receives a Sell from J.P. Morgan

TIPRANKS
·
17 Jul

IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine. -- Barrons.com

Dow Jones
·
17 Jul

JPMorgan Says to Short Tesla (TSLA), Moderna (MRNA), and 7 Other Stocks in 2025

TIPRANKS
·
13 Jul

Weekly Winners | Delta Air Soars 11%; Moderna, PTC Inc Gain 10%; Coinbase Surges 8.8%; Dollar Tree Rises 7%

Tiger Newspress
·
13 Jul

Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes

Simply Wall St.
·
13 Jul

Brookline Capital Markets Keeps Their Buy Rating on Moderna (MRNA)

TIPRANKS
·
11 Jul

Moderna Inc. Stock Rallies 4.5%, Outperforms Competitors

Dow Jones
·
11 Jul

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires Live
·
11 Jul

Moderna Shares Rise 3.8% After Full U.S. FDA Approval for Its Covid-19 Vaccine in Children Aged 6 Months Through 11 Years

THOMSON REUTERS
·
10 Jul

Rpt-Moderna: Expects to Have Its Updated Spikevax Vaccine Available for Eligible Populations in the U.S. for the 2025-2026 Respiratory Virus Season

THOMSON REUTERS
·
10 Jul

Rpt-Moderna Receives Full U.S. FDA Approval for Covid-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for Covid-19 Disease

THOMSON REUTERS
·
10 Jul

Morgan Stanley Remains a Hold on Moderna (MRNA)

TIPRANKS
·
10 Jul

Moderna Inc. Receives FDA Approval for Spikevax COVID-19 Vaccine in At-Risk Children Aged 6 Months to 11 Years

Reuters
·
10 Jul

Moderna Receives Full U.S. FDA Approval for Covid-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for Covid-19 Disease

THOMSON REUTERS
·
10 Jul

Moderna: Expects to Have Its Updated Spikevax Vaccine Available for Eligible Populations in the U.S. for the 2025-2026 Respiratory Virus Season

THOMSON REUTERS
·
10 Jul